Table 1 Baseline characteristics of the ITT population, by treatment arm and age. Reported as n (%) unless otherwise indicated
Characteristics | Arm A, 100 mg/m2 | Arm B, 125 mg/m2 | ||
|---|---|---|---|---|
Overall (N = 79) | Patients aged 75+ (N = 33) | Overall (N = 79) | Patients aged 75+ (N = 33) | |
Median age in years (range) | 72 (65–84) | 80 (75–84) | 73 (65–88) | 77 (75–88) |
Age | ||||
65–69 | 28 (35) | – | 21 (27) | – |
75+ | 33 (42) | 33 (100) | 33 (42) | 33 (100) |
ECOG PS | ||||
0 | 51 (65) | 20 (61) | 43 (54) | 19 (58) |
1 | 19 (24) | 9 (27) | 32 (41) | 13 (40) |
2 | 9 (11) | 4 (12) | 4 (5) | 1 (3) |
ADL scores | ||||
Impaired [range] | 14 (18) [5/6–4/6] | 6 (18) [5/6–5/6] | 20 (25) [5/6–1/6] | 8 (24) [5/6–1/6] |
Missing data | 2 (2) | 2 (2) | 0 | 0 |
IADL scores | ||||
Impaired [range] | 20 (25) [7/8–2/8] | 9 (3) [7/8–4/8] | 20 (25) [7/8–2/8] | 8 (24) [7/8–3/8] |
Missing data | 2 (2) | 1 (3) | 0 | 0 |
Comorbidities | ||||
Any grades 3–4 | 8 (10) | 6 (18) | 10 (13) | 3 (9) |
Diabetes mellitus | 9 (11) | 6 (18) | 11 (14) | 4 (12) |
HR status | ||||
ER− and PgR− | 9 (11) | 5 (15) | 8 (10) | 4 (12) |
ER+ and/or PgR+ | 68 (86) | 28 (85) | 67 (85) | 28 (85) |
Missing data | 2 (3) | 0 | 4 (5) | 1 (3) |
HER2 status | ||||
Positive | 2 (3) | 1 (3) | 0 | 0 |
Missing data | 5 (6) | 2 (6) | 10 (13) | 4 (12) |
Prior taxane use | 11 (14) | 3 (9) | 10 (13) | 1 (3) |
Measurable disease | 60 (76) | 22 (67) | 65 (82) | 28 (85) |
Visceral disease | 56 (71) | 22 (67) | 55 (69) | 25 (76) |